Compare Hinge Health Inc. Class A Common Stock (HNGE) vs InMode Ltd (INMD) Price & Performance

Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.

The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.

InMode (INMD) trades at $14.305, showing minimal daily movement with a 0.03% gain. The stock maintains a bullish technical signal despite mixed indicators, with RSI suggesting mild overbought conditions. Fundamentally, the company demonstrates strong profitability with 76.52% gross margins and 20.69% net income margins, though 2026 guidance shows potential margin compression. Recent developments include the launch of Morpheus8 Cool technology and an unsolicited acquisition offer from Steel Partners at $16.75 per share in July 2026.

The investment outlook balances attractive valuation metrics (P/E of 11.83, EV/EBITDA of 4.68) against cyclical industry headwinds and management capital allocation concerns. Analyst sentiment is divided with 45% buy ratings, while technicals suggest near-term consolidation around current levels. Key risks include US platform sales decline and execution on international growth strategy.